A new approach to Alzheimer’s — a pill containing a key feature of human cells called mitochondria — is being developed to treat the…
Drugmaker Cassava believes its experimental Alzheimer’s therapy, which sent the company’s stock values surging with a recent phase 2 study announcement, could beat Biogen’s…
Skeptics may have an extra reason to reconsider the upshots of vaccines: Two recent studies showed that flu and pneumonia vaccines reduced people’s risk…
Shedding further light on the mystery of Alzheimer’s pathology, a new study shows that individuals with a neurodegenerative language disorder called primary progressive aphasia…
New research paves the way for a future in which concussions — which are often missed — could be detected on the spot with…
While Biogen’s experimental Alzheimer’s treatment aducanumab faced yet another snag recently in its convoluted path toward FDA approval, other drugs companies are catching up:…
As part of our BrainTalk series, Being Patient spoke with Executive Director of ACADIA Pharmaceuticals Dr. Erin Foff and Chris Schwilk, who lives with…